What 6 Analyst Ratings Have To Say About Coherus BioSciences
Portfolio Pulse from Benzinga Insights
Over the past quarter, Coherus BioSciences (NASDAQ:CHRS) received 6 analyst ratings, with 4 being bullish and 2 somewhat bullish. There were no indifferent, somewhat bearish, or bearish ratings. The average price target is $13.83, which is significantly higher than the current price of $1.995. This target suggests a substantial upside but is a 1.21% decrease from the previous target of $14.00. Analysts derive their ratings from various sources, including company calls, financial statements, and insider information.
November 28, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coherus BioSciences has received 6 positive analyst ratings with an average price target of $13.83, suggesting a significant upside from the current price of $1.995. The price target has slightly decreased by 1.21% from the previous $14.00.
The unanimous positive ratings from analysts indicate a strong consensus on the stock's potential growth. The substantial difference between the current price and the target price suggests that the market may react positively in the short term, especially as the target price implies a significant upside. However, the slight decrease in the target price may temper expectations slightly, hence the confidence score is not at the maximum.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100